The Opportunity.
Biologics now make up over half of the global pharmaceutical pipeline, with the market projected to exceed $600 billion by 2030. Yet the industry’s ability to create new cell lines — the “factories” that make these drugs — is constrained by outdated technologies or costly licensing restrictions.
The result? Drug development delays, high costs, and missed opportunities for early-stage innovators.
Select XPress changes that.
Our Breakthrough.
Select XPress is a next-generation protein expression system built on a fundamental feature of the cells used in biopharmaceutical manufacturing.
We’ve discovered the first new selective marker for CHO cells in a generation and successfully applied it to the production of trastuzumab — demonstrating:
Significant productivity gains
compared to industry standards
Faster identification
of high-yield cell lines
Full freedom to operate
no restrictive licenses, no royalties
With Select XPress, biotech companies can move from discovery to manufacturing faster, at lower cost, and without legal barriers.
The Problem We Solve.
Current cell line development tools come with heavy commercial restrictions:
-
High license fees
-
Ongoing royalties
-
Limited access for small or early-stage companies
This locks many scientists out of industrial-grade expression systems at the very stage where speed and flexibility matter most.
Our Business Model.
For the first time, a leading-edge expression technology will be offered with complete freedom to operate.
Our revenue model is simple:
We sell the proprietary materials essential to running the Select XPress system. As the biologics pipeline grows and therapies progress toward market approval, we capture value at every stage.
The addressable market is massive — and growing. With biologics dominating pharma pipelines, our platform is positioned to become an industry standard.
Our Story.
Select XPress was born in the laboratory of Professor Dickson, during fundamental research into how cells grow and survive in manufacturing. Recognising the commercial potential, Dr Jonathan Dempsey of Pathway Biopharma and partnered with Professor Dickson to adapt this discovery into a market-ready platform.
Early funding from IBioIC and BBSRC allowed us to:
-
Validate the target
-
Build the materials for industrial application
-
Outperform industry-standard systems in early trials
These results gave us the confidence to make Select XPress the foundation of our company.
Why Now.
Market Timing
unprecedented growth in biologics R&D
First-mover Advantage
first new CHO marker in decades
Disruption Potential
removing licensing barriers opens a multimillion dollar global market in biopharmaceutical manufacturing
What We Need.
Partners
to evaluate Select XPress in production environments and act as early adopters
Investment
to scale commercialisation
